---
title: "Gan & Lee Pharmaceuticals. (603087.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603087.SH.md"
symbol: "603087.SH"
name: "Gan & Lee Pharmaceuticals."
industry: "Biotechnology"
datetime: "2026-05-20T22:46:56.747Z"
locales:
  - [en](https://longbridge.com/en/quote/603087.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603087.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603087.SH.md)
---

# Gan & Lee Pharmaceuticals. (603087.SH)

## Company Overview

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and other medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.ganlee.com.cn](https://www.ganlee.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 7 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.70% |  |
| Net Profit YoY | 23.31% |  |
| P/B Ratio | 2.76 |  |
| Dividend Ratio | 1.83% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 32742664053.68 |  |
| Revenue | 3952406204.32 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.85% | B |
| Profit Margin | 25.96% | A |
| Gross Margin | 74.56% | A |
| Revenue YoY | 13.70% | B |
| Net Profit YoY | 23.31% | B |
| Total Assets YoY | 3.22% | C |
| Net Assets YoY | 4.56% | C |
| Cash Flow Margin | 77.84% | C |
| OCF YoY | 13.70% | B |
| Turnover | 0.32 | D |
| Gearing Ratio | 6.72% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Gan & Lee Pharmaceuticals.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.70%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "23.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.76",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.83%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "32742664053.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3952406204.32",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.85%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "25.96%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "74.56%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.70%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "23.31%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.22%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.56%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "77.84%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "13.70%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "6.72%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 32.16 | 13/81 | 45.79 | 41.94 | 39.95 |
| PB | 2.79 | 42/81 | 3.78 | 3.41 | 3.04 |
| PS (TTM) | 8.35 | 39/81 | 10.99 | 10.09 | 9.62 |
| Dividend Yield | 1.81% | 16/81 | 2.37% | 1.77% | 1.51% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-10T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 55.15 |
| Highest Target | 77.00 |
| Lowest Target | 77.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603087.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603087.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603087.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603087.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**